Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 393,889
  • Shares Outstanding, K 266,141
  • Annual Sales, $ 10,120 K
  • Annual Income, $ -220,660 K
  • EBIT $ -257 M
  • EBITDA $ -249 M
  • 60-Month Beta 1.77
  • Price/Sales 34.98
  • Price/Cash Flow N/A
  • Price/Book 0.95

Options Overview Details

View History
  • Implied Volatility 72.43% ( -17.38%)
  • Historical Volatility 106.74%
  • IV Percentile 16%
  • IV Rank 9.40%
  • IV High 637.10% on 04/07/25
  • IV Low 13.86% on 09/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 106
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 4,074
  • Open Int (30-Day) 6,814

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.24
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.30
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1500 +33.04%
on 05/07/25
1.7200 -11.05%
on 04/23/25
+0.1000 (+6.99%)
since 04/17/25
3-Month
1.1050 +38.46%
on 04/11/25
2.1300 -28.17%
on 03/05/25
-0.4200 (-21.54%)
since 02/20/25
52-Week
1.1050 +38.46%
on 04/11/25
5.0000 -69.40%
on 10/18/24
-2.4900 (-61.94%)
since 05/20/24

Most Recent Stories

More News
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

AUTL : 1.5300 (+3.38%)
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

AUTL : 1.5300 (+3.38%)
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

AUTL : 1.5300 (+3.38%)
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

AUTL : 1.5300 (+3.38%)
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

AUTL : 1.5300 (+3.38%)
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

AUTL : 1.5300 (+3.38%)
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

AUTL : 1.5300 (+3.38%)
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

AUTL : 1.5300 (+3.38%)
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

AUTL : 1.5300 (+3.38%)
Autolus Therapeutics to Participate in Upcoming Investor Conferences

AUTL : 1.5300 (+3.38%)

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London,...

See More

Key Turning Points

3rd Resistance Point 1.6850
2nd Resistance Point 1.6200
1st Resistance Point 1.5750
Last Price 1.5300
1st Support Level 1.4650
2nd Support Level 1.4000
3rd Support Level 1.3550

See More

52-Week High 5.0000
Fibonacci 61.8% 3.5121
Fibonacci 50% 3.0525
Fibonacci 38.2% 2.5929
Last Price 1.5300
52-Week Low 1.1050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar